Watery diarrhea biotech Jaguar Animal Health files for a $70 million IPO


Shutterstock photo

Jaguar Animal Health, a biotech developing gastrointestinal treatments for companion and production animals, filed on Wednesday with the SEC to raise up to $70 million in an initial public offering. The company's lead drug candidate is for the treatment of watery diarrhea in dogs. 

The San Francisco, CA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol JAGX . BMO Capital Markets and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Watery diarrhea biotech Jaguar Animal Health files for a $70 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com